{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:54:30Z","timestamp":1793710470415,"version":"4.6.1"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T00:00:00Z","timestamp":1679702400000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ygyno.2022.01.021","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:35:30Z","timestamp":1643798130000},"page":"30-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI \u2013 GINECO study"],"prefix":"10.1016","volume":"165","author":[{"given":"Florence","family":"Joly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Follana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lequesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Medioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lesoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-S\u00e9bastien","family":"Frenel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Floquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Gladieff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Gavoille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Kalbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Briand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Brachet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Giffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis-Bastien","family":"Weiswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Alexandre","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Blanc-Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leconte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Poulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2022.01.021_bb0005","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0010","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IGC.0000000000000836","article-title":"Efficacy and safety of bevacizumab-containing therapy in newly diagnosed ovarian cancer: ROSiA single-arm phase 3b study","volume":"27","author":"Oza","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2022.01.021_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0025","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0030","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0035","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102111","article-title":"Newly diagnosed ovarian cancer: which first-line treatment?","volume":"91","author":"Lorusso","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0045","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0090-8258(02)00091-4","article-title":"A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"88","author":"Rose","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II trial of weekly paclitaxel (80 mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Gynecologic Oncology Group","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2007.08.062","article-title":"Weekly topotecan for recurrent platinum resistant ovarian cancer","volume":"108","author":"Abushahin","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0065","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0075","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0085","doi-asserted-by":"crossref","first-page":"59950","DOI":"10.18632\/oncotarget.19048","article-title":"The molecular mechanisms of chemoresistance in cancers","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0090","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nature03579","article-title":"An inhibitor of Bcl-2 family proteins induces regression of solid tumours","volume":"435","author":"Oltersdorf","year":"2005","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0095","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/14728214.2010.515210","article-title":"Emerging Bcl-2 inhibitors for the treatment of cancer","volume":"16","author":"Azmi","year":"2011","journal-title":"Expert Opin. Emerg. Drugs."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2006.12.011","article-title":"Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells","volume":"105","author":"Villedieu","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0105","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1158\/1078-0432.CCR-07-0362","article-title":"The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin","volume":"13","author":"Witham","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0110","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1158\/1535-7163.MCT-09-0493","article-title":"Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14\u20131 in cisplatin-resistant ovarian carcinoma cells","volume":"8","author":"Simonin","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/ijc.24787","article-title":"Bcl-XL and MCL-1 constitute pertinent targets in ovarian carcinoma and their concomitant inhibition is sufficient to induce apoptosis","volume":"126","author":"Brotin","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.01.021_bb0120","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1002\/ijc.29104","article-title":"Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma","volume":"136","author":"Lheureux","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.01.021_bb0125","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0130","doi-asserted-by":"crossref","first-page":"6902","DOI":"10.1021\/jm800669s","article-title":"Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins","volume":"51","author":"Park","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0135","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0140","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s10637-014-0116-3","article-title":"A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin\/paclitaxel in the treatment of patients with solid tumors","volume":"32","author":"Vlahovic","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2022.01.021_bb0150","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10637-014-0110-9","article-title":"A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors","volume":"32","author":"Cleary","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2022.01.021_bb0155","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Rudin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2288-3-6","article-title":"Design of Phase II cancer trials evaluating survival probabilities","volume":"3","author":"Case","year":"2003","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0170","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1200\/JCO.2013.49.7685","article-title":"PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer","volume":"31","author":"Naumann","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0175","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1200\/JCO.2012.45.1278","article-title":"Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant\/refractory epithelial ovarian cancer","volume":"31","author":"Vergote","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0180","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0185","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/gyno.1998.5125","article-title":"Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis","volume":"70","author":"Liu","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0190","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/labinvest.2014.139","article-title":"Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time","volume":"95","author":"Vassilakopoulou","year":"2015","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0195","doi-asserted-by":"crossref","first-page":"R76","DOI":"10.1186\/bcr2719","article-title":"Extreme loss of immunoreactive p-Akt and p-Erk1\/2 during routine fixation of primary breast cancer","volume":"12","author":"Pinhel","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0200","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00280-015-2882-9","article-title":"Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study","volume":"76","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0205","doi-asserted-by":"crossref","first-page":"1212369","DOI":"10.1155\/2019\/1212369","article-title":"Drugs and clinical approaches targeting the antiapoptotic protein: a review","volume":"2019","author":"Han","year":"2019","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2014.03.001","article-title":"PI3K\/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced","volume":"348","author":"Jebahi","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0215","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/jm500672y","article-title":"First evidence that oligopyridines, \u03b1-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies","volume":"58","author":"Gloaguen","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1158\/1535-7163.MCT-16-0342","article-title":"The mTORC1\/2 inhibitor AZD8055 strengthens the efficiency of the MEK inhibitor trametinib to reduce the Mcl-1\/[Bim and Puma] ratio and to sensitize ovarian carcinoma cells to ABT-737","volume":"16","author":"P\u00e9tigny-Lechartier","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0225","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41419-020-2588-8","article-title":"Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib","volume":"11","author":"Florent","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ygyno.2022.01.021_bb0230","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.2217\/fon-2021-0140","article-title":"A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors","volume":"17","author":"Puglisi","year":"2021","journal-title":"Future Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825822000488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:55Z","timestamp":1758772735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825822000488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0090825822000488"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI \u2013 GINECO study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}